Hans‐Jochem Kolb

Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial

Jürgen Finke, Wolfgang Bethge, Claudia Schmoor et al. · The Lancet Oncology · 2009 · 719 citations

Life Sciences, Hematology, Immunology +14

Long-Term Survival and Late Deaths after Allogeneic Bone Marrow Transplantation

Gèrard Socié, Judith V. Stone, John R. Wingard et al. · New England Journal of Medicine · 1999 · 701 citations · Full text

Public Health, Biostatistics, Hematology +12

Sequential Regimen of Chemotherapy, Reduced-Intensity Conditioning for Allogeneic Stem-Cell Transplantation, and Prophylactic Donor Lymphocyte Transfusion in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome

Christoph Schmid, Michael Schleuning, Georg Ledderose et al. · Journal of Clinical Oncology · 2005 · 419 citations

Medicine, Oncology, Cell Therapy +15

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants

Rüdiger Hehlmann, Michael Lauseker, Susanne Saußele et al. · Leukemia · 2017 · 339 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti–T-cell globulin ATG-Fresenius

Gèrard Socié, Claudia Schmoor, Wolfgang Bethge et al. · Blood · 2011 · 303 citations · Full text

Life Sciences, Immunology, Clinical Immunology +15